Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin and Parsaclisib in R/R T-Cell Lymphomas
NCT04774068Phase 1Completed
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of parsaclisib in Mature T-cell and NK-cell lymphoma (T/NKCL), primary cutaneous T-cell non-Hodgkin lymphoma (CTCL), anaplastic large cell lymphoma (ALCL) and 1 more. Primary endpoint: Maximum Tolerated Dose. Started Sep 2021; status: completed.
02
Drugs
parsaclisib
03
Conditions
Mature T-cell and NK-cell lymphoma (T/NKCL)primary cutaneous T-cell non-Hodgkin lymphoma (CTCL)anaplastic large cell lymphoma (ALCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT04774068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04774068.